PDCD6IP and prostate carcinoma: In this study, we investigated differences in expression of XPO1 and PDCD6IP on well‐characterized prostate cancer cohorts using mass spectrometry and tissue microarray (TMA) immunohistochemistry to determine their diagnostic and prognostic value.